Regression of posterior uveal melanoma following iodine-125 plaque radiotherapy based on pre-treatment tumor apical height

Miguel, David; Saornil, María A.; Frutos, Jesús María de; García-Álvarez, C.; Alonso, Pilar; Diezhandino, Patricia

doi:10.5114/jcb.2021.105278

Cited by 4 publications

(4 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More recently, other researchers have identified a different model of tumor response, which can be modeled by a negative exponential function for the first 7 years after treatment, depending on initial height, except for those less than 2.5 mm [ 23 ].…”

Section: Discussionmentioning

confidence: 99%

Radiological and clinical findings in uveal melanoma treated by plaque interventional radiotherapy (brachytherapy): Visual atlas and literature review on response assessment

Fionda¹,

Pagliara²,

Lancellotta³

et al. 2022

jcb

View full text Add to dashboard Cite

Uveal melanoma (UM) is the most common intra-ocular tumor in Caucasian adults and may derive from melanocytes. Historically, the first therapeutic approach to treat UM has been surgical removal of the eye, with obvious consequences in terms of function, cosmesis, and psychological impact on patients.Collaborative Ocular Melanoma Study (COMS) introduced the first uniform approach to perform interventional radiotherapy (IRT -brachytherapy) procedure in a standardized way that allowed to demonstrate equivalence of IRT with enucleation in terms of overall survival. Since this milestone, several international guidelines have been issued with regard to several technical aspects of this procedure, which has become the mainstream therapy worldwide. However, nowadays, there is still a lack of consensus about the criteria to definitively assess UM response after IRT.We present a collection of paradigmatic cases treated in our institution, and then discuss in detail the latest available evidence on the topic.

show abstract

Section: Discussionmentioning

confidence: 99%

Radiological and clinical findings in uveal melanoma treated by plaque interventional radiotherapy (brachytherapy): Visual atlas and literature review on response assessment

Fionda¹,

Pagliara²,

Lancellotta³

et al. 2022

jcb

View full text Add to dashboard Cite

show abstract

“…Physicians have used several radionuclides such as 125 I and 106 Ru to treat tumors. [4][5][6][7] In radiotherapy, the risk of normal tissue toxicity limits the dose that can be safely directed toward the tumor. Therefore, precise dosimetry is fundamental for both tumor dose prescription and the determination of the risk of normal tissue toxicity.…”

Section: Introductionmentioning

confidence: 99%

“…Ocular melanoma brachytherapy can provide patients with good long‐term results in terms of local tumor control. Physicians have used several radionuclides such as 125 I and 106 Ru to treat tumors 4–7 . In radiotherapy, the risk of normal tissue toxicity limits the dose that can be safely directed toward the tumor.…”

Section: Introductionmentioning

confidence: 99%

Evolution of dose distribution for a ¹²⁵I eye plaque using MCNPX and Plaque Simulator software

Poorbaygi,

Sardari,

Aghamiri

et al. 2024

Precision Radiation Oncology

View full text Add to dashboard Cite

ObjectiveEye plaque radiation therapy is the treatment of choice for small‐ and medium‐sized choroidal melanomas. This study investigated the dose distribution around eye plaques containing 125I seeds to treat ocular melanoma using Monte Carlo N‐Particle eXtended (MCNPX) and Plaque Simulator (PS) software.MethodsDosimetry evaluation and comparison of the resulting isodose curves for 125I COMS plaques were performed using the MCNPX code. The isodose curves and dose distributions were calculated using PS treatment planning for a 125I COMS plaque.ResultsIn the validation, the maximum relative difference between the results of this study and those reported in other literature was approximately 9%–10% for the COMS plaques. The dose distributions of MCNPX were lower than those of PS with a relative difference of approximately 27.7%–35.4%. The dose distribution may differ depending on the 125I source spectra and seed design used in the two methods. In addition, the dose algorithm used in PS made a major contribution to the relative differences between the results.ConclusionThe PS did not provide accurate details of dose distribution near the surface of the plaque insert. The source parameters used in each program should be studied more carefully to determine the source of the differences in the estimated dose values.

show abstract

“…Treatment involves placing a radioactive plaque on the surface of the eye near the tumor. Ocular melanoma brachytherapy can provide patients with good long-term results in terms of local tumor control; however, metastases are a major concern that often leads to vision or eye loss and in many cases lead to death (Messer JA et al 2020;Miguel D et al 2021). Physicians have used several radionuclides such as, 125 I and 106 Ru for treatment tumors (COMS Group 2006; Lommatzsch PK 1986: Simpson ER et al 2014, and also there are an experience in use of 192 Ir and 103 Pd 131 Cs (Valcarcel F et al 1994;Finger PT et al 2002).…”

Section: Introductionmentioning

confidence: 99%

Dosimetry evaluation of a new 169Yb-LDR COMS plaque for treatment of intraocular tumors

Sardari,

Poorbaygi,

Aghamiri

et al. 2023

Preprint

View full text Add to dashboard Cite

Ocular melanoma is the most common and malignant intraocular tumor with an incidence of one percent per thousand per year, which can lead to vision loss or even death. The present study investigated the dose distribution around ocular plaque containing 169Yb seeds to treat ocular melanoma. Dosimetry evaluation and comparison of the resulting isodose curve for 169Yb COMS plaque with 125I COMS plaque were performed using MCNPX code. The results of this comparison showed that with this choice, the time for ocular plaque implantation can be reduced by about 3 times for eye plaque with 20mm in diameter, which can be an important achievement for the treatment of large intraocular tumors. It was shown that for the 169Yb LDR source, a dose of 63 Gy (1.6 Gyh− 1) is equivalent to BED of 103.5 Gy and it is biologically equivalent to an 125I LDR of 85 Gy over 5 d. For critical points such as sclera the dose was minimized about %24 and 32% for tumor of apex 5 mm and 10 mm, respectively. For opposite side, it maximized only about %20 and 7% for tumor of apex 5 mm and 10 mm, respectively. Therefore, it seems that the use of 169Yb COMS plaque is better for the larger tumor apex. The results indicate that the 169Yb-LDR plaque can be suitable for treatment intraocular tumors with small basal dimension and larger in height.

show abstract

Regression of posterior uveal melanoma following iodine-125 plaque radiotherapy based on pre-treatment tumor apical height

Cited by 4 publications

References 54 publications

Radiological and clinical findings in uveal melanoma treated by plaque interventional radiotherapy (brachytherapy): Visual atlas and literature review on response assessment

Radiological and clinical findings in uveal melanoma treated by plaque interventional radiotherapy (brachytherapy): Visual atlas and literature review on response assessment

Evolution of dose distribution for a ¹²⁵I eye plaque using MCNPX and Plaque Simulator software

Dosimetry evaluation of a new 169Yb-LDR COMS plaque for treatment of intraocular tumors

Contact Info

Product

Resources

About

Regression of posterior uveal melanoma following iodine-125 plaque radiotherapy based on pre-treatment tumor apical height

Cited by 4 publications

References 54 publications

Radiological and clinical findings in uveal melanoma treated by plaque interventional radiotherapy (brachytherapy): Visual atlas and literature review on response assessment

Radiological and clinical findings in uveal melanoma treated by plaque interventional radiotherapy (brachytherapy): Visual atlas and literature review on response assessment

Evolution of dose distribution for a 125I eye plaque using MCNPX and Plaque Simulator software

Dosimetry evaluation of a new 169Yb-LDR COMS plaque for treatment of intraocular tumors

Contact Info

Product

Resources

About

Evolution of dose distribution for a ¹²⁵I eye plaque using MCNPX and Plaque Simulator software